Koutif Therapeutics aims to develop therapeutic compounds that inhibit the inflammatory cascade in a unique manner. Our current lead compound is based upon discoveries by Rama Mallampalli, MD and Beibei Chen, PhD on inhibitors of the ubiquitin degradation pathway that Koutif has licensed from the University of Pittsburgh.
Inflammation plays a critical role in the progression of many diseases. One way of modulating this process is through the degradation of key proteins (TRAFs) involved in the activation cascade. Fbxo3, an E3 ligase, is a negative regulator of this control process resulting in a continuation of the inflammation cascade. Drs. Mallampalli and Chen identified a specific inhibitor of Fbxo3 that acts to allow the degradation of several potent, pro-inflammatory proteins, including multiple proteins involved in adaptive and innate signaling pathways. This novel mechanism has the potential to treat numerous inflammatory conditions.
Koutif Therapeutics' lead compound, KT-1002, has reached clinical candidate status for the treatment of inflammatory bowel diseases, including ulcerative colitis and Crohn’s Disease, after successfully completing IND-enabling studies. The small molecule oral inhibitor also shows promise in the treatment of bronchiolitis obliterans syndrome, chronic obstructive pulmonary disease, acute lung injury, and rheumatoid arthritis.
Our technology is based on intellectual property exclusively licensed from the University of Pittsburgh and the United States Department of Veterans Affairs.